Martínez C, Carreras E, Rovira M, Urbano-Ispizua A, Esteve J, Perales M, Fernández F, Montserrat E
Institute of Hematology and Oncology, Department of Hematology, Postgraduate School of Hematology Farreras-Valenti, IDIBAPS, Hospital Clínic, University of Barcelona, Spain.
Bone Marrow Transplant. 2000 Sep;26(6):677-9. doi: 10.1038/sj.bmt.1702567.
Two patients with disseminated mantle-cell lymphoma relapsed 24 and 13 months, respectively, after high-dose chemotherapy and autologous stem cell transplantation (autoSCT). Both patients had an HLA-identical sibling and received an allogeneic stem cell transplant (alloSCT) 32 and 18 months after autologous transplant, after conditioning with fractionated 12 Gy total body irradiation plus cyclophosphamide 120 mg/kg. They are both alive and in complete remission 24 months after transplant. Both patients have developed chronic graft-versus-host disease and their Karnofsky performance status is 90%. AlloSCT may offer a useful approach in a subgroup of patients with mantle-cell lymphoma who have relapsed after autologous transplantation.
两名弥漫性套细胞淋巴瘤患者在接受大剂量化疗和自体干细胞移植（autoSCT）后，分别于24个月和13个月复发。两名患者均有一名HLA配型相同的同胞，并在自体移植后32个月和18个月接受了异基因干细胞移植（alloSCT），预处理方案为分次全身照射12 Gy加环磷酰胺120 mg/kg。移植后24个月，两名患者均存活且处于完全缓解状态。两名患者均发生了慢性移植物抗宿主病，其卡氏评分均为90%。对于自体移植后复发的套细胞淋巴瘤患者亚组，异基因干细胞移植可能是一种有效的治疗方法。
